NCT03709758View on ClinicalTrials.gov

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

December 1, 2025

Study Completion Date

June 1, 2026

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die

DRUG

Daunorubicin

Chemotherapy is most effective at killing cells that are rapidly dividing.

DRUG

Cytarabine

Chemotherapy is most effective at killing cells that are rapidly dividing.

Trial Locations (2)

60637

RECRUITING

University of Chicago, Chicago

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

AbbVie
Genentech, Inc.
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER